L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Rajiv Agarwal,Stefan D. Anker,George Bakris,Gerasimos Filippatos,Bertram Pitt,Peter Rossing,Peter Rossing,Luis M. Ruilope,Martin Gebel,Peter Kolkhof,Christina Nowack,Amer Joseph,Fidelio-Dkd,Figaro-Dkd Investigators +13 more
TL;DR: Two Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D and understudied yet high-risk cardiorenal subpopulations have the potential to widen the scope of therapy in T1D with CKD.
Journal ArticleDOI
How far should blood pressure be reduced in diabetic hypertensive patients
TL;DR: The optimal goal of blood pressure control in diabetics has not been established, but there are indications that it should be lower than the 130/85 mmHg systolic/diastolic pressure recommended by current guidelines.
Journal ArticleDOI
Acute renal excretory actions of losartan in spontaneously hypertensive rats: role of AT2 receptors, prostaglandins, kinins and nitric oxide.
Raquel Muñoz-García,Rosaura Maeso,Elena Rodrigo,J. Navarro,Luis M. Ruilope,M. C. Casal,Victoria Cachofeiro,V. Lahera +7 more
TL;DR: Nitric oxide participates in the antihypertensive action ofLosartan and Kinins, prostaglandins and nitric oxide appear to be involved in the effects of losartan on the glomerular filtration rate.
Journal ArticleDOI
Rationale, Design, and Baseline Characteristics of ARTS-DN : A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy
Luis M. Ruilope,Rajiv Agarwal,Juliana C.N. Chan,Mark E. Cooper,Ron T. Gansevoort,Hermann Haller,Giuseppe Remuzzi,Peter Rossing,Roland E. Schmieder,Christina Nowack,Anna C. Ferreira,Alexander Pieper,Nina Kimmeskamp-Kirschbaum,George L. Bakris +13 more
TL;DR: ARTS-DN is the first phase 2b trial of finerenone in combination with a RAS inhibitor in patients with type 2 diabetes mellitus and a clinical diagnosis of DN.
Journal ArticleDOI
Differential Effect of Chronic Antihypertensive Treatment on Vascular Smooth Muscle Cell Phenotype in Spontaneously Hypertensive Rats
Rosario Bravo,Beatriz Somoza,Mariano Ruiz-Gayo,Carmen G. Gonzalez,Luis M. Ruilope,María S. Fernández-Alfonso +5 more
TL;DR: It is suggested that long-term losartan treatment significantly changes VSMC phenotype and proliferative status, apparently unrelated to blood pressure lowering or to endothelial function improvements.